Tclin MPL Thrombopoietin receptor

Protein Summary

Description

Receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production. May represent a regulatory molecule specific for TPO-R-dependent immune responses. In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• P40238
• Q5JUZ0
• TPO-R

Gene Name

• MPL

Ensembl ID

• ENST00000372470
• ENSP00000361548
• ENSG00000117400

Symbol

• TPOR
• MPLV
• TPOR
• C-MPL
• CD110
• THPOR
• THCYT2

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
PubMedID	0.77
biological term	0.75
microRNA	0.73
tissue	0.67
phenotype	0.62

Protein Classes

PANTHER Classes

Protein / Receptor / Cytokine Receptor / Type I Cytokine Receptor / Thrombopoietin Receptor

DTO Classes

Protein / Receptor / Cytokine Receptor / Type I Cytokine Receptor / Thrombopoietin Receptor

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 867.99   (req: < 5)

Gene RIFs: 219   (req: <= 3)

Antibodies: 322   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 867.99   (req: >= 5)

Gene RIFs: 219   (req: > 3)

Antibodies: 322   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 12

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 179

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 4